Virtual Library

Start Your Search

M. Pesta



Author of

  • +

    P2.03b - Poster Session with Presenters Present (ID 465)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.03b-045 - Assessment of microRNAs in FFPE Tissue for Prediction of the Effect of Palliative Chemotherapy for Squamous Cell Carcinoma of the Lung (ID 4182)

      14:30 - 14:30  |  Author(s): M. Pesta

      • Abstract

      Background:
      Background: Due to their pathophysiological role and stability in biological samples, microRNAs have the potential to become valuable predictive markers for non-small cell lung cancer (NSCLC). Samples of biopsy tissue constitute suitable material for microRNA profiling with the aim of predicting the effect of palliative chemotherapy.

      Methods:
      Patients and Methods: Our study group consisted of 81 patients (74 males, 7 females, all of them smokers or former smokers) with late stage (3B, 4) of squamous cell carcinoma (SCC) histological subtype of NSCLC. All patients underwent palliative chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabin. The expression of 17 selected microRNAs was measured by quantitative RT PCR in tumor tissue macrodissected from formalin-fixed paraffin-embedded (FFPE) tissue samples. To predict the effect of palliative chemotherapy, the relationship between gene expression levels and overall survival (OS) was analysed.

      Results:
      Results: From the set of the 17 microRNAs of interest, we found relation of high expression levels of miR-34a and miR-224 to shorter OS.

      Conclusion:
      Conclusions: In routinely available FFPE tissue samples, we found microRNAs with a relation to OS, which may be candidate predictors of the effectiveness of palliative treatment in SCC lung cancer patients. Such microRNAs could help in decision about the type of palliative chemotherapy - patients with predicted poor treatment effect could be candidates to available clinical trials.